ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.  This receptor has been shown to play a role in the inflammatory response associated with metabolic diseases including type 2 diabetes, as well as other diseases including vascular restenosis following stent placement, and multiple sclerosis.  

Chronic inflammation is now thought to be central to the development of insulin resistance in type 2 diabetes.  Macrophages represent as much as 40% of the cell population in obese adipose tissue; the majority of these macrophages are derived from CCR2-positive monocytes recruited from the blood.  CCX140 is a potent and selective antagonist of the CCR2 chemokine receptor.  CCX140 works by blocking the monocyte/macrophage infiltration that occurs during inflammation and thus is designed to provide selective treatment of the disease without compromising other immune functions.  Successful completion of single and multiple ascending dose Phase I studies in healthy volunteers showed that CCX140 was safe and well-tolerated.  In preclinical models, CCX140 has demonstrated an efficacy profile similar to that of the glitazones, a class of drugs currently used for diabetes therapy, with CCX140 also exhibiting an improved safety profile exemplified by the absence of fluid retention and lack of drug-induced weight gain.  

CCX140 is chemically distinct from all other known antagonists of CCR2. Preclinical data show that the compound selectively inhibits CCR2-mediated migration of monocytes and does not inhibit migration mediated by other chemokine receptors, even when the compound is given at high doses. This high degree of target specificity is an important safety feature designed to allow CCX140 to be effective while avoiding unwanted side effects.

"The initiation of this Phase II trial for CCX140 is an important step forward in identifying a novel treatment for diabetes, a disease for which an unmet medical need for safe and convenient therapies persists," stated Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "We believe that CCX140 will be a meaningful treatment option not only for type 2 diabetes but also for diseases of the cardiovascular system, such as vascular restenosis following stent placement. This milestone represents yet another advance in our mission to deliver best-in-class chemokine-based therapies for inflammatory diseases."

Study Design

This randomized, double-blind, placebo- and active-controlled Phase II study is being conducted in patients with type 2 diabetes.  The study is expected to enroll approximately 140 patients.  Eligible patients will be randomized to one of four treatment groups as follows:  placebo once daily; pioglitazone hydrochloride at 30 mg once daily; CCX140 at 5 mg once daily and CCX140 at 10 mg once daily.  Dosing will be for 28 days with a 28-day follow-up period.  The primary objective of this study is to evaluate the safety and tolerability of CCX140 in subjects with type 2 diabetes based on incidence of adverse events.  Secondary endpoints in the study include fasting glucose and insulin concentrations, homeostasis model assessment of insulin resistance (HOMA-IR), glucose control based on HbA1c and serum total adiponectin concentrations.

Source:

ChemoCentryx, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Review of natural products with promising anti-SARS-CoV-2 potential